David Erlinge
391 – 400 of 505
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Development of a C5AR antagonist for the treatment of reperfusion injury
2010) 8th Joint Conference of the International-Cytokine-Society/International-Society-for-and-Cytokine-Re search In Cytokine 52(1-2). p.26-26(
- Contribution to journal › Published meeting abstract
-
Mark
Mild hypothermia markedly reduces ischemia related coronary t-PA release.
(
- Contribution to journal › Article
-
Mark
Prognostic effects of pre-hospital and in-hospital therapeutic interventions on 30-days mortality in patients with cardiogenic shock
(
- Contribution to journal › Published meeting abstract
-
Mark
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
(
- Contribution to journal › Article
-
Mark
Apyrase treatment of myocardial infarction according to a clinically applicable protocol fails to reduce myocardial injury in a porcine model
(
- Contribution to journal › Article
-
Mark
Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model
(
- Contribution to journal › Article
-
Mark
Cold saline and endovascular cooling induces rapid hypothermia before reperfusion in STEMI patients treated with primary PCI, is safe and reduces infarct size with a scattered myocardial salvage
(
- Contribution to journal › Published meeting abstract
-
Mark
Development of a C5AR Antagonist for the Treatment of Reperfusion Injury by Directed Evolution
2010) 16th International Conference of the Inflammation-Research-Association In Inflammation Research 59. p.288-288(
- Contribution to journal › Published meeting abstract
-
Mark
ADP mediates inhibition of insulin secretion by activation of P2Y13 receptors in mice.
(
- Contribution to journal › Article
-
Mark
The reversible oral P2Y(12) antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature.
(
- Contribution to journal › Article